<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151253">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01782989</url>
  </required_header>
  <id_info>
    <org_study_id>16586</org_study_id>
    <nct_id>NCT01782989</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)</brief_title>
  <acronym>TOGA</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled Study Evaluating ORACEA® in Subjects With Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul Yates, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MEDARVA Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized study to evaluate the efficacy and safety of ORACEA® in
      the treatment of geographic atrophy due to dry age-related macular degeneration (AMD).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of enlargement in area of geographic atrophy in the study eye during the treatment period.</measure>
    <time_frame>Month 6 and Month 30</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Month 6 and Month 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>ORACEA®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg doxycycline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORACEA®</intervention_name>
    <description>ORACEA® (40mg doxycycline) capsule daily for 24 months</description>
    <arm_group_label>ORACEA®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule daily for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 55 - 85.

          -  Best corrected visual acuity of 20/20 - 20/400 in the study eye

          -  Best corrected visual acuity of hand motion or better in the non-study eye

          -  Clinical diagnosis of geographic atrophy secondary to non-exudative age-related
             macular degeneration in at least one eye (study eye)

          -  Geographic atrophy lesions of ≥ 0.5 and ≤ 7.0 MPS disc areas

        Exclusion Criteria:

          -  History of or active presence of choroidal neovascularization secondary to exudative
             age-related macular degeneration in the study eye

          -  History of or active presence of choroidal neovascularization secondary to exudative
             age-related macular degeneration in the non-study eye requiring any treatment within
             12 months prior to Day 0 or expected to require treatment for the duration of the
             study

          -  Prior treatment for non-exudative age-related  macular degeneration

          -  Current or previous history of treatment of the study eye with any tetracycline
             derivative for any ocular condition.

          -  History of vitreoretinal surgery, corneal transplant, or laser photocoagulation in
             the study eye

          -  Any intraocular or periocular surgery within 90 days prior to Day 0 in the study eye.

          -  History of any hypersensitivity to tetracycline components

          -  Use of a tetracycline derivative therapy for a concurrent systemic or ocular disorder
             within 90 days of Day 0

          -  History of sensitivity to the sun
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A Yates, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Yates, MD, PhD</last_name>
    <phone>434-243-2852</phone>
    <email>klh7v@virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Holbrook</last_name>
      <phone>434-243-2852</phone>
      <email>klh7v@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Yates, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 6, 2013</lastchanged_date>
  <firstreceived_date>January 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Paul Yates, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>geographic atrophy</keyword>
  <keyword>non-exudative age-related macular degeneration</keyword>
  <keyword>macular degeneration</keyword>
  <keyword>dry macular degeneration</keyword>
  <keyword>dry AMD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Doxycycline hyclate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
